Jim Cramer Highlights ‘Transformational’ Impact Of Weight Loss Drugs Like Ozempic: Focus Now On ‘Potential Winners’ From The Same Narrative – Novo Nordisk (NYSE:NVO), Eli Lilly (NYSE:LLY)
What Happened: Jim Cramer outlined fresh investment prospects on Monday, revolving around the growing demand for GLP-1 drugs, typically administered for diabetes and obesity treatment. As reported by CNBC, investors…